No One Should Die Waiting for an Organ Transplant. These Doctors Want to Ensure That Doesn’t Happen
By Tanya Lewis,
Scientific American
| 10. 18. 2023
Robert Montgomery walked deliberately down the hospital hallway carrying a stainless-steel bowl containing a living human kidney resting on a bed of ice. Minutes earlier the organ had been in one man's body. It was about to be implanted into another man to keep him alive.
It was about 11 A.M. on a Monday this past spring. I followed Montgomery, an abdominal transplant surgeon and director of the NYU Langone Transplant Institute, into an operating room where 49-year-old John Primavera was waiting to receive the precious kidney. Monitors beeped; Shakira played on the sound system. Montgomery, who has performed thousands of transplants, walked up to the operating table and gently lowered the organ into Primavera's abdomen. The kidney, offered to Primavera by his close friend Thomas Kenny, was pale and about the size and shape of a mango. Montgomery motioned for me to step toward the table. I watched as he removed the clamps on the artery he had just sewn onto the replacement organ. The kidney flushed pink with blood and began to pulse with life.
This kidney transplant...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...